“Korea represents a sizable and strategic market opportunity for HDI, and
J. Y. Trading Co. is experienced in working with American firms and in
introducing medical technologies to physicians in Korea,” said Greg
Guettler, President of Hypertension Diagnostics. “Cardiovascular disease
(strokes and heart attacks) is the leading cause of death in Korea and the
majority of these deaths occur under 65 years of age. Of the approximate
47 million people living in South Korea, 25 percent of the adult
population (35-59 years old) suffer from hypertension and 5 percent suffer
from diabetes,” added Guettler.
J. Y. Trading Co. was founded during 1995 and currently distributes
through its six medical sales employees and ten independent sales
representatives. “J. Y. Trading Co. is dedicated to the distribution of
high quality medical products for cardiovascular disease,” said Jung-Yul
Kim, President of J. Y. Trading Co. “We have good relations with our
physicians in many major hospitals and prominent clinics that specialize
in diabetes and heart disease, and we are eager to begin distribution of
the CVProfilor® System following Korean Food and Drug
Administration (KFDA) approval. “Since high blood pressure and diabetes
are among the top five major diseases, we see HDI’s technology playing a
key role in Korea’s future,” added Mr. Kim.
Hypertension Diagnostics, Inc. designs, develops, manufactures and markets
proprietary cardiovascular profiling systems for medical applications and
clinical research. These systems are marketed to physicians, other health
care professionals and researchers by a direct sales force and via
distributors throughout the world. In addition to providing blood pressure
values, the systems non-invasively detect subtle changes in the compliance
or elasticity of both large and small arteries which is a unique feature
of HDI’s technology.
Forward-looking statements in this press release are made under the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995.
The Company wishes to caution readers not to place undue reliance on any
forward-looking statements and to recognize that the statements are not a
prediction of actual future results. Actual results could differ
materially from those presented and anticipated in the forward-looking
statements due to the risks and uncertainties set forth in the Company’s
2001 Annual Report on Form 10-KSB under the caption “Risk Factors,” as
well as others not now anticipated.
CVProfilor is a registered trademark of Hypertension Diagnostics, Inc.
Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of
Hypertension Diagnostics, Inc. All rights reserved.
Investor Relations: Jens Dalsgaard and Tony Altavilla,
Managing Directors
Redwood Consultants, LLC
Mill Valley, CA 94941
415-380-0500
Contact: Greg H. Guettler, President
